{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:34:40Z","timestamp":1786642480402,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.7759\/cureus.114485","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:58:42Z","timestamp":1786640322000},"source":"Crossref","is-referenced-by-count":0,"title":["Early Recognition of Neuroleptic Malignant Syndrome Without Hyperthermia: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Temebi W","family":"Andafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheriffdeen A","family":"Adekanmbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijioke M","family":"Ugwumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woyengidoubara T","family":"Angaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godbless  N","family":"Oyinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulikhat","family":"Maruwf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06438","article-title":"An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method","volume":"72","author":"Gurrera RJ","year":"2011","unstructured":"Gurrera RJ, Caroff SN, Cohen A, et al.. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011, 72:1222-8. 10.4088\/JCP.10m06438","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","year":"2013","unstructured":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Association, Washington, DC; 2013. 10.1176\/appi.books.9780890425596"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.24018\/ejmed.2021.3.6.1035","article-title":"Symptom frequencies and correlations with temperature variations in suspected cases of neuroleptic malignant syndrome (NMS)","volume":"3","author":"Velamoor V","year":"2021","unstructured":"Velamoor V, Mann SC, Woodbury MA, Cernovsky ZZ. Symptom frequencies and correlations with temperature variations in suspected cases of neuroleptic malignant syndrome (NMS). Eur J Med Health Sci. 2021, 3:51-7. 10.24018\/ejmed.2021.3.6.1035","journal-title":"Eur J Med Health Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.37897\/RJN.2022.1.8","article-title":"Frequency of pattern of clinical and laboratory features in patients presenting with neuroleptic malignant syndrome","volume":"21","author":"Amrat S","year":"2022","unstructured":"Amrat S, Bullo N, Kumar D, et al.. Frequency of pattern of clinical and laboratory features in patients presenting with neuroleptic malignant syndrome. Ro J Neurol. 2022, 21:45-53. 10.37897\/RJN.2022.1.8","journal-title":"Ro J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.105189","article-title":"Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics","volume":"201","author":"Trollor JN","year":"2012","unstructured":"Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012, 201:52-6. 10.1192\/bjp.bp.111.105189","journal-title":"Br J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"156","author":"Gurrera RJ","year":"1999","unstructured":"Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999, 156:169-80. 10.1176\/ajp.156.2.169","journal-title":"Am J Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00137-9","article-title":"Thermoregulatory dysfunction in neuroleptic malignant syndrome","volume":"39","author":"Gurrera RJ","year":"1996","unstructured":"Gurrera RJ, Chang SS. Thermoregulatory dysfunction in neuroleptic malignant syndrome. Biol Psychiatry. 1996, 39:207-12. 10.1016\/0006-3223(95)00137-9","journal-title":"Biol Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23220","article-title":"Neuroleptic malignant syndrome: mechanisms, interactions, and causality","volume":"25","author":"Gillman PK","year":"2010","unstructured":"Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010, 25:1780-90. 10.1002\/mds.23220","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312438215","article-title":"Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register","volume":"2","author":"Chang CK","year":"2012","unstructured":"Chang CK, Harrison S, Lee W, Taylor D, Stewart R. Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register. Ther Adv Psychopharmacol. 2012, 2:75-83. 10.1177\/2045125312438215","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1994.tb03080.x","article-title":"Incidence of \"typical cases\" and \"incomplete cases\" of neuroleptic malignant syndrome and their epidemiological study","volume":"48","author":"Tsutsumi Y","year":"1994","unstructured":"Tsutsumi Y, Yamamoto K, Matsuura S, et al.. Incidence of \"typical cases\" and \"incomplete cases\" of neuroleptic malignant syndrome and their epidemiological study. Psychiatry Clin Neurosci. 1994, 48:777-84. 10.1111\/j.1440-1819.1994.tb03080.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.10.1344","article-title":"Frequency and presentation of neuroleptic malignant syndrome: a prospective study","volume":"144","author":"Keck PE Jr","year":"1987","unstructured":"Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry. 1987, 144:1344-6. 10.1176\/ajp.144.10.1344","journal-title":"Am J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00767-9","article-title":"Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study","volume":"34","author":"Lao KS","year":"2020","unstructured":"Lao KS, Zhao J, Blais JE, et al.. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs. 2020, 34:1165-75. 10.1007\/s40263-020-00767-9","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab062","article-title":"Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort","volume":"47","author":"Guinart D","year":"2021","unstructured":"Guinart D, Taipale H, Rubio JM, Tanskanen A, Correll CU, Tiihonen J, Kane JM. Risk factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort. Schizophr Bull. 2021, 47:1621-30. 10.1093\/schbul\/sbab062","journal-title":"Schizophr Bull"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2024.0047","article-title":"Incidence of neuroleptic malignant syndrome during antipsychotic treatment in children and youth: a national cohort study","volume":"34","author":"Ray WA","year":"2024","unstructured":"Ray WA, Fuchs DC, Olfson M, Stein CM, Murray KT, Daugherty J, Cooper WO. Incidence of neuroleptic malignant syndrome during antipsychotic treatment in children and youth: a national cohort study. J Child Adolesc Psychopharmacol. 2024, 34:397-406. 10.1089\/cap.2024.0047","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-015-0162-5","article-title":"Neuroleptic malignant syndrome: complications, outcomes, and mortality","volume":"24","author":"Modi S","year":"2016","unstructured":"Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016, 24:97-103. 10.1007\/s12028-015-0162-5","journal-title":"Neurocrit Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson JL","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985, 142:1137-45. 10.1176\/ajp.142.10.1137","journal-title":"Am J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.10.1227","article-title":"Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital","volume":"143","author":"Pope HG Jr","year":"1986","unstructured":"Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986, 143:1227-33. 10.1176\/ajp.143.10.1227","journal-title":"Am J Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145799001388","article-title":"Proposed research diagnostic criteria for neuroleptic malignant syndrome","volume":"2","author":"Mathews T","year":"1999","unstructured":"Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol. 1999, 2:129-44. 10.1017\/S1461145799001388","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome","volume":"77","author":"Caroff SN","year":"1993","unstructured":"Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993, 77:185-202. 10.1016\/S0025-7125(16)30278-4","journal-title":"Med Clin North Am"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890420249.dsm-iv-tr","article-title":"Diagnostic and Statistical Manual of Mental Disorders text revision (DSM-IV-TR)","year":"2000","unstructured":"Diagnostic and Statistical Manual of Mental Disorders text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC; 2000. 10.1176\/appi.books.9780890420249.dsm-iv-tr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000640","article-title":"A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome","volume":"37","author":"Gurrera RJ","year":"2017","unstructured":"Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2017, 37:67-71. 10.1097\/JCP.0000000000000640","journal-title":"J Clin Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S45084","article-title":"Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome","volume":"9","author":"Nisijima K","year":"2013","unstructured":"Nisijima K, Shioda K. Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome. Neuropsychiatr Dis Treat. 2013, 9:853-9. 10.2147\/NDT.S45084","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref23","article-title":"Epidemiology of neuroleptic malignant syndrome","volume":"22","author":"Adityanjee","year":"1999","unstructured":"Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol. 1999, 22:151-8.","journal-title":"Clin Neuropharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2006.10.004","article-title":"Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence","volume":"48","author":"Gurrera RJ","year":"2007","unstructured":"Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007, 48:205-11. 10.1016\/j.comppsych.2006.10.004","journal-title":"Compr Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.8.1113","article-title":"Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique","volume":"155","author":"Hasan S","year":"1998","unstructured":"Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998, 155:1113-6. 10.1176\/ajp.155.8.1113","journal-title":"Am J Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.159.5.709","article-title":"The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?","volume":"159","author":"Rosebush PI","year":"1991","unstructured":"Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?. Br J Psychiatry. 1991, 159:709-12. 10.1192\/bjp.159.5.709","journal-title":"Br J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517301-early-recognition-of-neuroleptic-malignant-syndrome-without-hyperthermia-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:58:43Z","timestamp":1786640323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517301-early-recognition-of-neuroleptic-malignant-syndrome-without-hyperthermia-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.114485","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}